Related Experiment Video
Updated: Sep 30, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone Deacetylase 1 Depletion Alleviates Coronary Heart Disease Via the MicroRNA-182-Mediated Transforming Growth
Shengkai Zhou1, Peng Liu, Guobao Zhang
1Department of Cardiovascular Surgery, Fuwai Central China Cardiovascular Hospital, The People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, P.R. China.
Insights
Histone deacetylase 1 (HDAC1) worsens coronary heart disease (CHD) by repressing miR-182, which activates the TGF-β/Smad pathway. Downregulating HDAC1 improves cardiac function and reduces injury in CHD rats.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Epigenetics
Background:
- Histone deacetylases (HDACs) regulate gene expression by controlling histone acetylation.
- HDAC inhibitors have shown potential in suppressing cardiomyocyte growth.
- The specific role of HDAC1 in coronary heart disease (CHD) progression requires further investigation.
Purpose of the Study:
- To investigate the role of HDAC1 in the pathogenesis of coronary heart disease (CHD).
- To elucidate the regulatory mechanism of HDAC1 on microRNA-182 (miR-182) expression.
- To determine the impact of the HDAC1/miR-182 axis on the transforming growth factor (TGF)-β/Smad pathway in CHD.
Main Methods:
- Epigenetic probe array and chromatin immunoprecipitation for HDAC1 and miR-182 analysis.
- MicroRNA microarray to identify downstream targets of HDAC1.
- In vivo studies in CHD rats using various biochemical and histological assays.
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Western blot.
Main Results:
- HDAC1 was overexpressed in CHD patients and repressed miR-182 expression in rat cardiomyocytes via deacetylation.
- Downregulation of HDAC1 improved cardiac function, normalized lipid profiles, and reduced myocardial injury and inflammation in CHD rats.
- miR-182 downregulation exacerbated cardiac injury in the context of HDAC1 knockdown.
- HDAC1/miR-182 modulated the TGF-β/Smad pathway, with HDAC1 activating it and miR-182 inhibiting it.
Conclusions:
- HDAC1 plays a crucial role in promoting CHD by repressing miR-182 expression.
- The HDAC1-mediated repression of miR-182 leads to the activation of the TGF-β/Smad pathway, contributing to CHD progression.
- Targeting the HDAC1/miR-182 axis presents a potential therapeutic strategy for managing coronary heart disease.
Abstract:
Histone deacetylase (HDAC) determines the acetylation status of histones, thereby regulating gene expression. HDAC inhibitors have been demonstrated to suppress cardiomyocyte growth in vitro and in vivo. We assessed here whether HDAC1 exerts an aggravating effect on coronary heart disease (CHD). Epigenetic probe array revealed that HDAC1 was overexpressed in patients with CHD. HDAC1 was then downregulated in rat cardiomyocytes, and microRNA microarray analysis was performed to detect downstream targets of HDAC1, followed by chromatin immunoprecipitation validation. HDAC1 inhibited miR-182 expression through deacetylation. miR-182 was poorly expressed in patients with CHD. Using enzyme-linked immunosorbent assay, Reverse transcription-quantitative PCR, hematoxylin-eosin staining, terminal deoxynucleotidyl transferase (TdT)-mediated 2'-deoxyuridine 5'-triphosphate (dUTP) nick-end labeling assay, and immunohistochemistry, we observed that HDAC1 downregulation promoted cardiac function, restored lipid levels, reduced myocardial injury markers and inflammatory factors, and alleviated myocardial tissue damage and apoptosis in CHD rats. By contrast, miR-182 downregulation exacerbated injury in rats in the presence of HDAC1 knockdown. Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that the target genes of miR-182 were mainly enriched in the transforming growth factor (TGF)-β/Smad pathway. Western blot also validated that HDAC1/miR-182 modulated the TGF-β/Smad pathway activity. Our results demonstrated that HDAC1 repressed miR-182 and activated the TGF-β/Smad pathway to promote CHD.
Related Concept Videos
TGF - β Signaling Pathway
Coronary Artery Disease II: Pathophysiology
Hedgehog Signaling Pathway

